Advicenne Solidifies UK Foothold as Global Ambitions Hinge on US Decision

PARIS, France – July 01, 2026 – French pharmaceutical firm Advicenne S.A. has secured a significant victory in one of Europe's key markets, receiving an unlimited renewal of its Marketing Authorization for Sibnayal® in the United Kingdom. The decision by the Medicines and Healthcare products Regulatory Agency (MHRA) ensures long-term access to the treatment for UK patients suffering from distal Renal Tubular Acidosis (dRTA), a rare and debilitating kidney disease. While a crucial milestone for patients and a testament to the drug's safety profile, this regulatory validation is a calculated move in a much larger game. For Advicenne, the UK approval serves as another fortified position in a global campaign that now turns its focus to the ultimate prize: the American market.

The Unmet Need in a Rare Disease

To understand the significance of sustained access to Sibnayal®, one must first grasp the profound impact of dRTA. This rare genetic disorder prevents the kidneys from properly excreting acid, leading to its accumulation in the blood. The consequences, particularly for children, are severe and lifelong. Patients often experience stunted growth, rickets, and chronic bone pain. Internally, the condition can cause the formation of kidney stones and calcium deposits (nephrocalcinosis), which can progressively lead to chronic kidney disease and eventual renal failure.

For decades, treatment has been a grueling ordeal. The standard of care involved consuming alkali solutions, such as citrate salts or bicarbonate, multiple times a day. "The treatment burden is immense," noted one nephrologist familiar with the condition. "We're asking children and adults to adhere to a regimen of frequent, often unpalatable doses, including waking up during the night. Compliance is a constant struggle, and inconsistent treatment allows the underlying acidosis to continue its damaging course."

Sibnayal®, a prolonged-release formulation of potassium citrate and potassium bicarbonate, was designed specifically to address these challenges. Its twice-daily dosing regimen dramatically reduces the treatment burden, improving the quality of life for patients and their caregivers. Clinical data has consistently shown its ability to effectively control metabolic acidosis over the long term. The MHRA's decision for an unlimited renewal, which follows a mandatory five-year review of the drug's performance and safety data since its initial 2021 approval, definitively validates its therapeutic value and cements its place as a critical treatment option in the UK.

A Pattern of Global Regulatory Success

This UK renewal is not an isolated event but the latest in a string of strategic regulatory and commercial wins for Advicenne. The company has been methodically building a global footprint for Sibnayal®, demonstrating an adept ability to navigate complex international pharmaceutical landscapes. This latest approval follows a similar unlimited marketing authorization renewal in the European Union, which became effective in January 2026, solidifying its presence across the continent.

Beyond Europe, the company has successfully expanded into the Middle East, securing marketing authorizations in the Kingdom of Saudi Arabia (July 2025) and the United Arab Emirates (January 2026). This expansion is particularly strategic, given that dRTA has a higher prevalence in the Gulf region compared to Western countries. Crucially, the company has also secured reimbursement status in the UAE and, as of February 2026, in its home market of France, transitioning Sibnayal® from an early access program to full commercial availability.

Each approval and reimbursement agreement is a building block, creating stable, recurring revenue streams and reinforcing the company's credibility. The firm's 2025 results reflected this momentum, with European end-market sales for Sibnayal® surging by over 71% to nearly €11 million. These incremental victories are essential for a specialty pharma company funding an ambitious pipeline.

High Stakes in the American Market

The most significant test for Advicenne lies just ahead. All eyes are now on the U.S. Food and Drug Administration (FDA), which is reviewing the New Drug Application (NDA) for Sibnayal® (known as ADV7103 in development). The agency has set a Prescription Drug User Fee Act (PDUFA) target action date of September 3, 2026. An approval would unlock access to the world’s largest and most lucrative pharmaceutical market.

Securing an FDA green light would be transformative for Advicenne. The drug already holds Orphan Drug Designation in the US, which provides market exclusivity and other development incentives. A successful launch in the United States, likely with a commercial partner the company is actively seeking, would dramatically alter its financial trajectory and elevate its status from a European niche player to a global competitor in the rare nephrology space.

Navigating Financials and the Future Pipeline

This global ambition requires significant capital, and Advicenne's financial journey has been closely watched. The company reported a net loss of €9.53 million in 2025, driven by R&D investments related to the very FDA submission that now holds its future. Earlier this year, its cash position raised concerns about its runway. However, the management has moved decisively to shore up its finances. Following a capital increase and debt restructuring in 2025, the company announced today a new bond financing of up to €3.8 million, a move designed to extend its cash runway into the second quarter of 2027—well past the critical FDA decision date.

Beyond dRTA, Advicenne has aspirations for ADV7103 in treating cystinuria, another rare kidney disease with a patient population significantly larger than dRTA's. While the drug holds orphan status for this indication in both the US and Europe, the path forward has become more complex. In a curious move, the company withdrew its late-stage European trial for cystinuria in January 2026, citing a "strategic business decision." This suggests a pivot or re-evaluation of its European strategy for the indication, even as it continues to pursue a development plan in the US. This strategic wrinkle adds a layer of uncertainty to its long-term growth story, placing even greater weight on the impending decision for Sibnayal® in dRTA.